Item 7.01 Regulation FD Disclosure

Beginning on January 9, 2023, senior executives of Cocrystal Pharma, Inc. (the "Company") will hold a series of meetings with the members of the scientific and financial community. A copy of the Company's presentation to be used in connection with these meetings is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits



Exhibit   Description

99.1        Cocrystal Pharma, Inc. Corporate Presentation, dated January 9, 2023
104       Cover Page Interactive Data File (embedded within the Inline XBRL
          document)

© Edgar Online, source Glimpses